Cancer Detection and Progression (CDP)
Areas Reviewed
- Biomarker identification and pre-clinical development, including liquid biopsy and molecular imaging
- Pre-clinical modeling to identify factors (such as microbiota, pathogens, nutrition, metabolism, oxygen levels, oncogenes, and tumor suppressor genes) and their mechanisms of action contributing to cancer progression
- Mechanisms of therapeutic response, including tumor evolution and treatment resistance
- Mechanisms of treatment-associated morbidities
Peer Review Committee Members
Co-chair, Vera Tarakanova, PhD, Medical College of Wisconsin
Co-chair, Christopher Willey, MD, PhD, University of Alabama
Community Research Partner, Karen Dupske
Community Research Partner, Miguel Melendez
Sally Adebamowo, ScD, University of Maryland School of Medicine
Sanjay Aneja, MD, Yale University
Chad Brenner, PhD, University of Michigan
Grace Chen, MD, PhD, University of Michigan
Claudette St. Croix, PhD, University of Pittsburgh
Lukas Dow, PhD, Weill Cornell Medicine
Joan Garrett, PhD, University of Cincinnati; James L. Winkle College of Pharmacy
Jessie Yanxiang Guo, PhD, Rutgers Cancer Institute of New Jersey
Rebecca Leary, PhD, Novartis
Zibo Li, PhD, UNC Chapel Hill
James Robinson, PhD, University of Minnesota
Lucas Salas, PhD, Darthmouth College
Mala Shanmugam, PhD, Emory University
David Soto-Pantoja, PhD, Wake Forest University
Shannon Stott, PhD, Massachusetts General Hospital
Wei Qiu, PhD, Loyola University
Zhaoming Wang, PhD, St. Jude Children's Research Hospital
Liangzhong Xiang, PhD, University of California, Irvine
Xuehong Zhang, MBBS, ScD, Harvard University
